A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

Lead Sponsor

AbbVie (prior sponsor, Abbott)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Adult subjects with moderately to severely active rheumatoid arthritis
•Subjects must have a DAS28(CRP) (Disease Activity Score using C-Reactive Protein) greater than or equal to 3.2 at baseline (there is no minimum CRP score required to qualify)
•Subjects must have at least 5/68 tender joints plus 5/66 swollen joints assessed at screening or baseline
•Subject must treated with and MTX (methotrexate) dose (oral and/or injectable) of 15 mg or more per week (no upper limit on dose) for at least 12 weeks prior to screening
•Subject is either biologic-naïve or has only one prior biologic disease-modifying antirheumatic drug (i.e. abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, or tocilizumab)

•Previous exposure to adalimumab (Humira), rituximab (Rituxan), natalizumab (Tysabri), efalizumab (Raptiva)
•Subject has been treated with intra-articular or parenteral administration of corticosteroids within 4 weeks of screening
•Subject has diagnosis or history of gout or pseudogout
•Subject has undergone joint surgery within 12 weeks of screening (at joints to be assessed by ultrasound)
•Subject has history of chronic arthritis diagnosed before age 16 years

Related studies

NCT07171983 · Rheumatoid Arthritis

NCT05869955 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, and more

NCT07558850 · Rheumatoid Arthritis, Dermatomyositis, and more

NCT07536529 · Inflammatory Joint Diseases, Rheumatoid Arthritis (RA), and more

NCT06329401 · Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, and more